1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 41, 14/Oct/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.41.2100920
2021-10-14
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.41.2100920
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/41/eurosurv-26-41-2.html?itemId=/content/10.2807/1560-7917.ES.2021.26.41.2100920&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Weekly epidemiological update on COVID-19 - 14 September 2021. Edition 57. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---14-september-2021
  2. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021;26(28):2100563.  https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563  PMID: 34269175 
  3. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.  https://doi.org/10.1136/bmj.i4919  PMID: 27733354 
  4. Pouwels KB, Pritchard E, Matthews P, Stoesser NB, Eyre DW, Vihta K-D, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv. 2021:2021.08.18.21262237v1.  https://doi.org/10.1101/2021.08.18.21262237 
  5. Puranik A, Lenehan PJ, Silvert E, Niesen MJ, Corchado-Garcia J, O’Horo JC, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021:2021.08.06.21261707v3.  https://doi.org/10.1101/2021.08.06.21261707 
  6. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy M, Greene D, Lutterloh E, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1150-5.  https://doi.org/10.15585/mmwr.mm7034e1  PMID: 34437517 
  7. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021.  https://doi.org/10.1016/S0140-6736(21)02183-8 
  8. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617.2) variant in Qatar. medRxiv. 2021:2021.08.11.21261885v1.  https://doi.org/10.1101/2021.08.11.21261885 
  9. Pramod S, Govindan D, Ramasubramani P, Kar SS, Aggarwal R. Effectiveness of Covishield vaccine in preventing Covid–19—A test–negative case–control study. medRxiv. 2021:2021.07.19.21260693v1.  https://doi.org/10.1101/2021.07.19.21260693 
  10. Elliott P, Haw D, Wang H, Eales O, Walters C, Ainslie K, et al. REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021. London: Imperial College London; 2021. Available from: https://spiral.imperial.ac.uk/handle/10044/1/90800
  11. Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, et al. Rapid increase in circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - Mesa County, Colorado, April-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1084-7.  https://doi.org/10.15585/mmwr.mm7032e2  PMID: 34383734 
  12. Keegan L, Truelove SA, Lessler J. Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah. medRxiv. 2021:2021.08.09.21261554v1.  https://doi.org/10.1101/2021.08.09.21261554 
  13. Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S, et al. Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 NCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B.·1.617.2 Delta variant despite reduced virus neutralisation. SSRN. 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3884946
  14. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021:2021.05.22.21257658.  https://doi.org/10.1101/2021.05.22.21257658 
  15. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv. 2021:2021.06.28.21259420v2.  https://doi.org/10.1101/2021.06.28.21259420 
  16. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) Variant—National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-6.  https://doi.org/10.15585/mmwr.mm7034e3  PMID: 34437519 
  17. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2.  https://doi.org/10.1016/S0140-6736(21)01358-1  PMID: 34139198 
  18. Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv. 2021:2021.07.28.21261295.  https://doi.org/10.1101/2021.07.28.21261295 
  19. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, HEROES-RECOVER Cohorts. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1167-9.  https://doi.org/10.15585/mmwr.mm7034e4  PMID: 34437521 
  20. Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B. 1.617. 2) variant. London: Public Health England; 2021. Available from: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Thomas+Harder&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harder Thomas</a>, <a href="/search?value1=Wiebe+K%C3%BClper-Schiek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Külper-Schiek Wiebe</a>, <a href="/search?value1=Sarah+Reda&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reda Sarah</a>, <a href="/search?value1=Marina+Treskova-Schwarzbach&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Treskova-Schwarzbach Marina</a>, <a href="/search?value1=Judith+Koch&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Koch Judith</a>, <a href="/search?value1=Sabine+Vygen-Bonnet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vygen-Bonnet Sabine</a>, <a href="/search?value1=Ole+Wichmann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wichmann Ole</a></span>. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(41):pii=2100920. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Sept 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Oct 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.41.2100920
/content/10.2807/1560-7917.ES.2021.26.41.2100920
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error